Micronutrient Composition for Depression and Multi-Pathway IL-6 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Inflammation and increased cytokine production, particularly IL-6, contribute to brain dysfunction, depression, and mental impairments, with existing treatments like anti-IL-6 receptor monoclonal antibodies being limited in scope.
Innovation Solution
A pharmaceutical micronutrient composition comprising L-theanine, Rhodiola rosea, ALCAR, Bacopa monnieri, Mucuna pruriens, NAD+, Rose hips extract, American Ginseng, Pyrroloquinone quinone, Gotu Kola, and CoQ10, formulated for oral, transdermal, rectal, or vaginal administration, to support brain health and nervous system function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-IL-6 receptor monoclonal antibodies are used to treat inflammation, then IL-6 secretion is inhibited, but the treatment scope is limited and does not address multiple inflammatory pathways
Solution Approach 1:
The patent combines multiple micronutrients (magnesium, zinc, vitamin C, vitamin D, omega-3 fatty acids, curcumin, resveratrol, quercetin, green tea catechins, and various B vitamins) into a single composition that works synergistically to inhibit IL-6 secretion through multiple pathways, thereby expanding treatment scope beyond what single agents can achieve
Solution Approach 2:
The invention uses a composite formulation of diverse micronutrients with different mechanisms of action, where each component contributes to anti-inflammatory effects through unique pathways, creating a multi-faceted treatment approach that addresses both IL-6 inhibition and broader inflammatory modulation
2Ease of operation
If a single micronutrient is used to treat depression, then the treatment is simple, but the efficacy is insufficient compared to combination therapy
Solution Approach 1:
The patent merges multiple micronutrients known to have individual antidepressant properties into a unified composition, where each component (magnesium, zinc, omega-3s, B vitamins, etc.) addresses different aspects of depression pathophysiology, achieving enhanced efficacy while maintaining ease of administration as a single formulation
Solution Approach 2:
The micronutrient composition serves multiple functions simultaneously: it reduces inflammation, supports neurotransmitter synthesis, protects neuronal cells, and modulates stress response systems, thereby providing comprehensive depression treatment through a single multi-functional formulation
3Reliability
If high doses of individual micronutrients are administered, then therapeutic effect is enhanced, but the risk of side effects and toxicity increases
Solution Approach 1:
The patent optimizes the dosage parameters of each micronutrient within safe therapeutic ranges, where the combination of multiple nutrients at moderate doses produces synergistic effects that achieve high therapeutic reliability without the toxicity associated with high doses of individual supplements
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Micronutrient compositions, comprising NAD+ in the range of 0.1 mg to 20,000 mg, American Ginseng in the range of 1 mg to 50,000 mg, and Pyrroloquinone quinone in the range of 0.1 mg to 50,000 mg improve brain health and nervous system functions. Various combinations of formulas were used. Formulas 12,10 and 5 shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.